옵션 체인은 다양한 행사가격과 만기일에 대한 GitLab의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 GitLab에 대한 시장 심리를 평가합니다..

GitLab (NASDAQ:GTLB) 주식, 옵션 체인

GITLAB INC-CL A

GitLab

GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.

Cathie Wood Defies CoreWeave IPO Slump, Ark Snaps Up $3.6 Million Worth Of Stock In Nvidia-Backed Company

Equities

News

Markets

ETFs

ARKK

GTLB

HOOD

PATH

RPTX

목요일(3일) 캐시 우드가 이끄는 아크 인베스트는 로빈후드 마켓츠(NASDAQ:HOOD)의 주식을 매입하며 의미 있는 행보를 보였다. 이번 전략적 투자는 로빈후드가 플랫폼을 지속적으로 확장하고 금융 서비스 제공을 강화하면서 이루어졌다.

아크 인베스트, 관세로 인한 매도세 속 로빈후드 주식 139만 달러 상당 매입

What Happened

AAPL

ARKW

CRWV

월요일(31일) 캐시 우드가 이끄는 아크 인베스트가 코어위브(NASDAQ:CRWV)와 로빈후드 마켓츠(NASDAQ:HOOD)와 관련해 주목할 만한 거래를 진행했다.

아크 인베스트, IPO 이후 급락한 코어위브 주식 360만 달러 규모 매입

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

ARKG

IRDM

캐시 우드의 화요일 대형 거래: 아크 인베스트는 템퍼스AI 주가 하락 속 780만 달러 투자

GitLab Inc

<a href="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/" title="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/">https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/</a>

CHDN

DKNG

FLUT

GAMB

PENN

WYNN

Reported June 1, 2025: 'New Taxes On Sports Bets, Nicotine Products As Democrats Pass $55.2B Budget' - Capital News Illinois

Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) stock is trading lower on Monday after reporting <a href="https://www.benzinga.com/pressreleases/25/06/g45717713/saic-announces-first-quarter-of-fiscal-year-2026-results">the first-quarter 2026 earnings</a>.
The company reported&nbsp;quarterly sales growth&nbsp;of 2% year-on-year to $1.88 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.87 billion.
The adjusted EPS of $1.92&nbsp;missed the analyst consensus&nbsp;estimate of $2.22.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45720002/campbells-brews-up-strong-q3-beats-estimates-as-home-cooking-sector-simmers">Campbell&#8217;s Brews Up Strong Q3: Beats Estimates As Home Cooking Sector Simmers</a>
Operating income for the quarter declined by 8% to $121 million, and the operating margin declined by 70 basis points to 6.4%.
Adjusted EBITDA decreased 5% to $157 million with an adjusted EBITDA margin of 8.4%, a 60 basis points decline.
Net bookings for the quarter were approximately $2.4 billion, which reflects a book-to-bill ratio of 1.3.&nbsp;
The quarter&#8217;s operating cash flow totaled $100 million. Free cash flow was an outflow of $44 million.
SAIC&#8217;s estimated backlog for the quarter was approximately $22.3 billion, of which $3.3 billion was funded. As of May 2, 2025, the company held $47 million in cash and equivalents.
CEO Toni Townes-Whitley acknowledged the steady progress it made against its enterprise growth strategy despite a still dynamic operating environment.
Science Applications <a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">reiterated the 2026</a> revenue outlook of $7.60 billion-$7.75 billion, below the analyst consensus estimate of $7.93 billion.
The company maintained an annual adjusted EPS outlook of $9.10-$9.30 below the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a> of $10.24.
Price Action: SAIC shares are trading lower by 10.7% to $103.21 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45716922/taiwan-semiconductor-eyes-uae-gigafab-seeks-crucial-us-green-light" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Eyes UAE Gigafab, Seeks Crucial US Green Light</a></li>
</ul>
Photo by DCStockPhotography via Shutterstock

Earnings

Guidance

Movers

Tech

SAIC

SAIC Stock Falls After Q1 Earnings Miss, Soft Guidance

Rivian Automotive, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock traded lower Monday by about 2.86% after the electric vehicle company announced plans to offer $1.25 billion in senior secured green notes due 2031 in <a href="https://www.benzinga.com/pressreleases/25/06/b45717976/rivian-automotive-inc-announces-proposed-1-25-billion-senior-secured-green-notes-offering-to-refin" target="_blank" rel="noreferrer noopener">a private offering</a>.
The EV manufacturer plans to use the offering proceeds and cash on hand to redeem $1.25 billion of outstanding floating rate senior secured notes due 2026 and pay related fees and expenses.
Rivian held $7.2 billion in <a href="https://www.benzinga.com/pressreleases/25/05/b45235082/rivian-releases-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">cash and equivalents</a> as of March 31.
Also Read: <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" target="_blank" rel="noreferrer noopener">This Tesla Rival Taps AI Expert Aidan Gomez To Drive Innovation</a>
Riavian stock is up close to 10% year-to-date and over 27% in the last 12 months.
Rivian had a better-than-expected <a target="_blank" href="https://www.benzinga.com/25/05/45642153/rivian-ceo-rj-scaringe-touts-45000-rivian-r2s-updated-rear-suspension-cant-wait-for-folks" rel="noreferrer noopener">first quarter 2025</a>, reporting quarterly revenue of $1.24 billion, a 3% increase. However, Rivian&nbsp;slashed its delivery projections&nbsp;for 2025 amid tariff uncertainty, which could raise the company&#8217;s cost per vehicle.
Rivian CEO RJ Scaringe had <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45617151/ubs-maintains-neutral-rating-for-rivian-stock-sets-price-13-price-target" target="_blank" rel="noreferrer noopener">voiced the company&#8217;s</a> plans for the R2, which is seen as an affordable option in Rivian&#8217;s otherwise costly line-up of SUVs and Pickup trucks.
The car maker also expanded its facility in Normal, Illinois, with a $120 million investment, which could create hundreds of jobs as the company reaffirmed its U.S.-centric supply chain.
CNBC&#8217;s Jim Cramer&nbsp;said&nbsp;Rivian <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45562808/jim-cramer-rivian-better-than-this-automaker-pan-american-silver-is-the-best-silver-mine" target="_blank" rel="noreferrer noopener">is better than</a>&nbsp;Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Price Action: Rivian shares are trading lower at aruond $14.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45717955/chinas-nio-clocks-13-deliveries-growth-in-may-tesla-lags" target="_blank" rel="noreferrer noopener">China&#8217;s NIO Clocks 13% Deliveries Growth In May, Tesla Lags</a></li>
</ul>
Image: Shutterstock

Bonds

Offerings

LCID

RIVN

Rivian Stock Goes Red After Offering $1.25 Billion Green Bond To Refinance 2026 Debt

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $322 to $273.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $273

VivoPower to leverage BitGo's best-in-class OTC trading desk and custody platform to build digital asset treasury strategy
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- BitGo, the leading infrastructure provider of digital asset solutions, and VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, "VivoPower"))), a publicly traded company that recently announced transition to an XRP focused treasury and decentralized finance solutions company, today announced a strategic partnership. VivoPower, having successfully raised US$121 million, will leverage BitGo as an exclusive over-the-counter (OTC) trading desk to acquire XRP for its initial US$100 million acquisition of XRP tokens.
VivoPower will exclusively leverage BitGo for both the trading of its XRP holdings through BitGo's 24/7/365 OTC trading desk and holding of its assets through BitGo's best-in-class custody platform. As a result, VivoPower is expected to benefit from BitGo's liquidity, robust execution capabilities, and secure cold storage infrastructure.

VVPR

VivoPower Forms Strategic Partnership With BitGo To Launch $100M XRP Acquisition And Digital Asset Treasury Strategy Using BitGo's Premier OTC Trading Desk and Custody Platform

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and raises the price target from $366 to $416.

Barclays Maintains Overweight on HCA Healthcare, Raises Price Target to $416

<a href="https://www.dallasfed.org/banking/events/2025/25banking">https://www.dallasfed.org/banking/events/2025/25banking</a>
&nbsp;
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Fed's Logan Says Despite Uncertainty, Financial Market Volatility, Us Economy Is Resilient; Labor Market Is Stable; Inflation Still Somewhat Above Target; Risks Are Balanced On Both Sides Of Mandate; If Tariffs Change Inflation Expectations That Would Be Significant; Market Volatility, Uncertainty Could Cause Households, Businesses To Pull Back; Monetary Policy Well Positioned To Wait, Be Patient; Well-Positioned To Act If Risks Materialize

Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.

Uranium Energy Q3 EPS $(0.07) Down From $(0.05) YoY

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $522 to $480.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $480

Rumors

Trading Ideas

Watching V.F. Corporation; Hearing Popular Newsletter Picks Stock

Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Overweight and raises the price target from $14 to $22.

REPL

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $22

<a href="https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702">https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702</a>
&nbsp;

SWBI

'Supreme Court Won't Hear Challenge To Maryland Assault Weapons Ban' - NBC News

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $82 to $79.

Barclays Maintains Overweight on CVS Health, Lowers Price Target to $79

U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Monday.
Following the market opening Monday, the Dow traded down 0.72% to 41,967.43 while the NASDAQ fell 0.38% to 19,040.92. The S&amp;P 500 also fell, dropping, 0.58% to 5,877.58.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate stocks fell by 1.5%.
Top Headline
The Campbell&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) posted better-than-expected third-quarter results on Monday.
The company reported third-quarter sales growth of 4% year over year (Y/Y) to $2.475 billion, beating the analyst consensus estimate of $2.43 billion. Adjusted EPS of $0.73 beat the consensus estimate of $0.66.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares shot up 486% to $28.90 after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.</li>
<li>Shares of InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) got a boost, surging 194% to $7.31.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares were also up, gaining 113% to $0.2455. Oragenics recently announced a 1-for-30 reverse stock split.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares dropped 31% to $5.64.</li>
<li>Shares of SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) were down 34% to $50.45 after the company announced a mixed-shelf offering</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) was down, falling 30% to $0.7457 after the company announced it commenced a public offering of pre-funded warrants.</li>
</ul>
Commodities In commodity news, oil traded up 3.1% to $62.67 while gold traded up 2.5% at $3,398.50.
Silver traded up 3.9% to $34.330 on Monday, while copper rose 4.5% to $4.8865.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.6%, while Spain's IBEX 35 Index fell 0.3%. London's FTSE 100 fell 0.3%, Germany's DAX 40 dipped 0.8% and France's CAC 40 fell 0.7% during the session.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei falling 1.30%, Hong Kong's Hang Seng Index dipping 0.57% and India's BSE Sensex declining 0.1%.
Economics
<ul class="wp-block-list">
<li>The ISM Manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.</li>
<li>U.S. construction spending declined by 0.4% month-over-month to an annual rate of $2,152.4 billion in April following a revised 0.8% fall in March.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to a reading of 52 in May versus a preliminary reading of 52.3.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

LYRA

MULN

OGEN

SBET

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Alliance Global Partners analyst Matthew Venezia initiates coverage on Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) with a Buy rating and announces Price Target of $12.

Initiation

PLUR

Alliance Global Partners Initiates Coverage On Pluri with Buy Rating, Announces Price Target of $12

General

HCLTech and UiPath Announce Strategic Partnership To Drive Large-Scale Transformation For Enterprises Across Industries

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 5 years by 4.07% on an annualized basis producing an average annual return of 17.0%. Currently, Travelers Companies has a market capitalization of $61.76 billion. 
Buying $100 In TRV: If an investor had bought $100 of TRV stock 5 years ago, it would be worth $231.02 today based on a price of $272.60 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748873713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Travelers Companies 5 Years Ago Would Be Worth This Much Today

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/pressreleases/25/06/b45717442/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and-co-comme" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate.
Also Read: <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion</a>
BioNTech&#8217;s BNT327 is currently under extensive evaluation in multiple ongoing clinical trials, with over 1,000 patients having received the treatment to date. 
These evaluations include global Phase 3 trials with registrational potential, investigating BNT327 as a first-line treatment for both extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). 
Furthermore, BioNTech plans to initiate an additional global Phase 3 trial by the end of 2025 to assess the candidate&#8217;s efficacy in treating triple-negative breast cancer (TNBC).
Under the terms of the agreement, the companies will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. 
Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
Bristol Myers Squibb will pay BioNTech $1.5 billion in an upfront payment and $2 billion in non-contingent anniversary payments through 2028.
These tax-deductible charges will be recorded as Acquired IPR&amp;D Expense when incurred, with the $1.5 billion being incurred in Q2.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
BioNTech and Bristol Myers Squibb will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and Bristol-Myers Squibb.
In May, Bristol-Myers Squibb agreed to pay $350 million to the State of Hawaii to settle claims related to the prescription drug Plavix, an antiplatelet drug that prevents blood clots by keeping platelets in the blood from coming&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" rel="noreferrer noopener">together and making clots</a>.
The agreement resolves a lawsuit filed by the state that alleged the pharmaceutical company engaged in deceptive practices surrounding the development, labeling, and marketing of the drug.
Price Action: BNTX stock is trading higher by 14.8% to $109.95, and BMY stock is trading lower by 0.62% to $47.98 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asset-sales/25/06/45721138/dow-exits-dowaksa-jv-stays-course-on-best-owner-strategy" target="_blank" rel="noreferrer noopener">Dow Exits DowAksa JV, Stays Course On &#8216;Best-Owner&#8217; Strategy</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

BNTX

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

U.S. stocks settled mixed on Friday, with the Dow Jones index gaining more than 50 points during the session after President Donald Trump accused China of "totally" breaching a tariff agreement, raising new fears over trade disputes.
Wall Street closed on a positive note last month, with the S&amp;P 500 gaining more than 6.2% in May and the Nasdaq jumping 9.6%. Both indices recorded their strongest months since November 2023. The Dow surged 3.9% for the month.
For the week, the S&amp;P 500 climbed, while the 30-stock Dow climbed 1.6%. The tech-laden Nasdaq, meanwhile, surged 2% last week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Leo Mariani
<ul class="wp-block-list">
<li>Analyst Firm: Roth Capital</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Maintained a Buy rating on Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) and cut the price target from $38 to $37 on May 27. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: On May 21, Sable Offshore announced a $200 proposed public offering.</li>
</ul>
Analyst: Richard Davis
<ul class="wp-block-list">
<li>Analyst Firm: Canaccord Genuity</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained a Hold rating on Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) and raised the price target from $100 to $115 on May 28. This analyst sees around 12% surge in the stock.</li>
<li>Recent News: On May 27, Okta reported first-quarter revenue of $688 million, beating analyst estimates of $680.25 million. The company reported adjusted earnings of 86 cents per share, beating analyst estimates of 77 cents per share.</li>
</ul>
Analyst: Trevor Walsh 
<ul class="wp-block-list">
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) and increased the price target from $240 to $310 on May 30. This analyst sees around 13% upside in the stock.</li>
<li>Recent News: On May 29, Zscaler reported third-quarter revenue of $678.03 million, beating the consensus estimate of $666.86 million.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Neutral rating on Cavco Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a price target of $550 on May 27. This analyst sees around 27% upside in the stock.</li>
<li>Recent News: On May 22, Cavco Industries posted upbeat quarterly results.</li>
</ul>
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained a Buy rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and boosted the price target from $205 to $210 on May 29. This analyst sees around 56% upside in the stock.</li>
<li>Recent News: On May 28, Nvidia reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 billion.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

CVCO

NVDA

OKTA

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE
SINGAPORE, June 2, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or "HBNB") and JVSPAC Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) ("JVSPAC") announced today that the United States Securities and Exchange Commission ("SEC") has declared effective Hotel101's registration statement on Form F-4 filed with the SEC in connection with the previously announced business combination agreement between Hotel101 and JVSPAC.
JVSPAC has scheduled the Extraordinary General Meeting of Shareholders ("EGM") on June 24, 2025 to vote on the proposed business combination with Hotel101.
The business combination values Hotel101 at an equity value of US$2.3 billion. The closing of the business combination is expected to occur as soon as possible, subject to regulatory and shareholder approvals and other customary closing conditions. Upon listing, the combined company will operate as Hotel101 Global Holdings Corp. and trade under the ticker symbol "HBNB". Once listed, Hotel101 will become the first Filipino-owned company to be listed and traded on Nasdaq. Hotel101 is a subsidiary of Philippine-listed DoubleDragon Corporation (PSE: DD).

JVSA

U.S. SEC Declares Hotel101's Form F-4 Registration Effective As JVSPAC Sets June 24 Shareholder Meeting To Vote On Proposed Business Combination; Upon Listing, The Combined Co Will Operate As Hotel101 Global Holdings Corp. And Trade Under The Ticker Symbol "HBNB"

Press Releases

GitLab Chief Financial Officer Brian Robins to Present at the 2025 Cantor Fitzgerald Global Technology Conference

GitLab Reports Fourth Quarter and Full Fiscal Year 2025 Financial Results

GITLAB INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GitLab Inc. - GTLB

GITLAB INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GitLab Inc. - GTLB

GitLab Wins a Google Cloud Technology Partner of the Year Award for DevOps

GitLab Announces the General Availability of GitLab Duo with Amazon Q

GitLab Announces GitLab 18 with AI-Native Capabilities to Increase Developer Productivity

Comments

GitLab

GitLab (GTLB) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌